Duloxetine
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Major Depressive Disorder
Conditions
Major Depressive Disorder
Trial Timeline
Aug 1, 2004 โ Mar 1, 2006
NCT ID
NCT00191932About Duloxetine
Duloxetine is a approved stage product being developed by Eli Lilly for Major Depressive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00191932. Target conditions include Major Depressive Disorder.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01391221 | Approved | UNKNOWN |
| NCT01363284 | Pre-clinical | Completed |
| NCT01089621 | Approved | Withdrawn |
| NCT01051466 | Approved | Completed |
| NCT00989157 | Phase 3 | Completed |
| NCT01074151 | Pre-clinical | Completed |
| NCT00889369 | Approved | UNKNOWN |
| NCT01754493 | Approved | Completed |
| NCT01028352 | Pre-clinical | Completed |
| NCT00696774 | Approved | Completed |
| NCT00532480 | Approved | Completed |
| NCT00529789 | Phase 2 | Completed |
| NCT00696293 | Approved | Completed |
| NCT00517985 | Approved | Completed |
| NCT00398632 | Approved | Terminated |
| NCT00401258 | Approved | Completed |
| NCT00438971 | Approved | Completed |
| NCT00531895 | Approved | Completed |
| NCT00322621 | Approved | Completed |
| NCT01035073 | Approved | Completed |
Competing Products
20 competing products in Major Depressive Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |
| LY2216684 + Sertraline | Eli Lilly | Phase 1 | 33 |
| LY2216684 + Placebo + Lorazepam | Eli Lilly | Phase 1 | 33 |
| LY2216684 + SSRI | Eli Lilly | Phase 3 | 77 |